Products
First RECRUIT-TandAb® AFM13 entered clinical trials in 2010!
click the image to see it in full size
Lead Products
TandAbs® are widely applicable and indicate superior therapeutic benefits in a broad range of diseases. In September 2010, Affimed initiated phase I clinical trials for its lead drug AFM13 to treat Hodgkin Lymphoma. In this phase I study the dose is being gradually escalated in order to assess safety and tolerability in Hodgkin Lymphoma patients.
AFM11 for the treatment of Non-Hodgkin Lymphoma (NHL) is in formal pre-clinical development and GMP manufacturing. AFM11 binds to the molecular targets on cancer (CD19) and cytotoxic T cells (CD3). AFM11 has been validated for expression in CHO, product stability, safety and animal pharmacology.
Product Pipeline
AFM13 binds to CD30 on malignant Reed-Sternberg cells and engages NK-cells through binding to CD16A leading to specific lysis of the tumor cells.
AFM11 binds to CD19 on malignant B cells and engages T cells through binding to CD3 leading to specific lysis of the tumor cells.
|
Compound
-
(target)
|
Indication |
Discovery |
Preclinical |
Phase I |
Phase II |
|
AFM13
-
(CD30xCD16A)
|
Hodgkin Lymphoma |
100% completed
|
100% completed
|
90 %
100%
|
|
|
AFM11
-
(CD19xCD3)
|
Non-Hodgkin Lymphoma |
100% completed
|
80 %
100%
|
100%
|
|
Discovery Portfolio
We have been building a growing pipeline of discovery and preclinically staged TandAbs® targeting autoimmune diseases and tumors. In addition, for more than 10 tumor targets antibodies are available that can be converted into TandAbs®.
Our Discovery Portfolio
TandAb® Technology
TandAbs® are tetravalent bispecific antibody formats. They bind to target molecules on the surface of tumor cells and T-cells or NK-cells leading to the lysis of the target cells.
TandAbs® possess the same avidity and affinity for each target as an IgG. When compared to IgGs and alternative antibody formats/scaffolds, TandAbs® possess a much higher efficacy.
In addition, TandAbs® appear to be safe in animals and humans.
A robust production and downstream processing for TandAbs® has been established in mammalian cells. The TandAb® molecules show high expression levels and display excellent stability.
TandAb® RECRUIT
Affimed´s original know-how of the activation process of cytotoxic immune cells, such as natural killer (NK) cells and cytotoxic T-cells, and the ability to isolate specific antibodies and generate novel antibody formats was crucial to the development of RECRUIT-TandAb®.
TandAb® RECRUIT
TandAb® BIBLOCK / PROLONG
A further cornerstone of our platform are PROLONG-TandAbs® and BiBLOCK-TandAbs®. The unique advantage offered is the simultaneous blocking of targets and a prolonged serum half-life. This approach promises a much better safety in comparison to IgG as TandAbs® have no Fc-mediated side effects.
TandAb® BIBLOCK
TandAb® PROLONG
